Vor Biopharma Files 8-K: Officer/Director Changes & Financials
Ticker: VOR · Form: 8-K · Filed: Sep 30, 2024 · CIK: 1817229
| Field | Detail |
|---|---|
| Company | Vor Biopharma Inc. (VOR) |
| Form Type | 8-K |
| Filed Date | Sep 30, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $464,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes, financials
TL;DR
Vor Bio leadership shakeup and financial updates filed 9/30.
AI Summary
Vor Biopharma Inc. filed an 8-K on September 30, 2024, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The filing also includes Regulation FD disclosures and financial statements and exhibits.
Why It Matters
This filing indicates potential shifts in the company's leadership and governance, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with compensatory arrangements, can signal internal shifts that may affect company strategy and performance.
Key Players & Entities
- Vor Biopharma Inc. (company) — Registrant
- September 30, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 100 Cambridgepark Drive, Suite 101, Cambridge, Massachusetts 02140 (address) — Principal Executive Offices
FAQ
What specific changes occurred regarding directors or officers?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers.
What is the date of the earliest event reported in this 8-K?
The date of the earliest event reported is September 30, 2024.
What is Vor Biopharma Inc.'s state of incorporation?
Vor Biopharma Inc. is incorporated in Delaware.
Where are Vor Biopharma Inc.'s principal executive offices located?
The principal executive offices are located at 100 Cambridgepark Drive, Suite 101, Cambridge, Massachusetts 02140.
What other types of information are included in this 8-K filing besides officer and director changes?
The filing also includes Regulation FD disclosures and financial statements and exhibits.
Filing Stats: 1,195 words · 5 min read · ~4 pages · Grade level 11.2 · Accepted 2024-09-30 07:05:52
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share VOR Nasdaq Glob
- $464,000 — er Letter provides for a base salary of $464,000 per year and a target annual bonus equa
Filing Documents
- d829992d8k.htm (8-K) — 32KB
- d829992dex991.htm (EX-99.1) — 10KB
- g829992g0926193456156.jpg (GRAPHIC) — 2KB
- 0001193125-24-228399.txt ( ) — 175KB
- vor-20240930.xsd (EX-101.SCH) — 3KB
- vor-20240930_lab.xml (EX-101.LAB) — 18KB
- vor-20240930_pre.xml (EX-101.PRE) — 11KB
- d829992d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release, dated September 30, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vor Biopharma Inc. Date: September 30, 2024 By: /s/ Robert Ang Robert Ang Chief Executive Officer